Previous investigators have found a statistically robust correlation in modulation of VEGF and sVEGFR2 patient plasma levels with exposure to sunitinib, and have proposed that such inhibition may be correlated with tumor response in patients with GIST and renal cell carcinoma 10. This evidence concerns the gene VEGFA and gastrointestinal stromal tumor.